Building A GMP-Ready Cell Line Development Strategy From Day One – Part 2: The Case For An Integrated, GMP-Ready Approach

By John Gill, VP & Scientific Leader of Cell Line Development at Abzena

Establishing a current Good Manufacturing Practice (cGMP)-ready cell line development strategy early in the drug creation lifecycle shifts downstream manufacturing outcomes from a high-risk gamble to a predictable execution. Rather than treating cell line creation, analytical method development, and scale-up as isolated development phases, an integrated model embeds quality and regulatory expectations into every step.

By utilizing advanced expression platforms, high-performing host cells, and stable pool technologies, development teams can decouple toxicology material manufacturing from final clone selection. Generating representative material early accelerates analytical development, downstream process locking, and formulation testing, saving valuable time on the critical path to Investigational New Drug (IND) filing. Aligning cell line screening with scale-up manufacturing parameters preserves vital process knowledge, ensures pool-to-clone product quality consistency, and prevents costly late-stage re-optimization.